For example, researchers have recently developed a novel strategy by engineering Tregs to express a chimeric antigen receptor targeting the interleukin-23 receptor, thereby generating IL-23R CAR-Tregs as a potential therapy for Crohn’s disease (193). This evidence concerns the gene IL23R and Crohn disease.